# GRANEXIN AS A TOPICAL THERAPEUTIC TO MITIGATE CUTANEOUS RADIATION INJURY

> **NIH NIH N01** · XEQUEL BIO, INC. · 2022 · $2,657,130

## Abstract

Radiation Injury Description: Granexin® gel is an easy-to-use, stable, topically applied gel containing the short regulatory peptide (aCT1) that possesses potent anti-inflammatory properties and accelerates cutaneous wound healing. FirstString Research proposes to further validate the efficacy, safety, and therapeutic potential of Granexin in the mitigation and treatment of CRI. The proposed development efforts will support NDA submission to the FDA for Granexin as a medical countermeasure (MCM) for CRI under the Animal Rule.

## Key facts

- **NIH application ID:** 10589744
- **Project number:** 75N93021C00009-P00003-9999-1
- **Recipient organization:** XEQUEL BIO, INC.
- **Principal Investigator:** GUATAM CHATNEKAR
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $2,657,130
- **Award type:** —
- **Project period:** 2021-03-16 → 2023-03-15

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10589744

## Citation

> US National Institutes of Health, RePORTER application 10589744, GRANEXIN AS A TOPICAL THERAPEUTIC TO MITIGATE CUTANEOUS RADIATION INJURY (75N93021C00009-P00003-9999-1). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10589744. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*